Manager Project

Nathan A. Zautke abnp0d@r.postjobfree.com

*** ****** **. ****: 303-***-****

Erie, CO. 80516 Mobile: 650-***-****

Objective

Having spent the last 8 years in both academic and drug discovery laboratories, I have come to new

fruitions that drive me to a more business and people based interest. I find market research to be an

excellent transition for me to apply my knowledge from the bench, along with my strong business

acumen, to pursue my goals for a business based career..

Education

Bachelors of Science: Cellular and Molecular Biology, April 27th 2001. Fort Lewis College, Durango CO.

Overall G.P.A. 3.7 Magna cum Laude

Science G.P.A. 3.9

-Senior Seminar Project- Oxygen Dissociation in Baxter Hemoglobin Therapeutics’ Hemoglobin Based

Oxygen Carriers Optro (rHb1.1™) and rHb0.1™ in Comparison with Natural Human Hemoglobin.

Employment History

October 2008-present

Research Associate III

Array BioPharma, Inc Drug discovery for oncology and inflammation diseases

Enzymology/HTS

-Promotion; List of tasks below.

-Lead biologist on new target. Responsibilities include designing, developing, and running a High

Throughput Screen assay for hit generation from entire in-house library

August 2007-October 2008

Research Associate II

Array BioPharma, Inc

Enzymology/HTS

-Remain diligent in finding new technologies and bringing them in-house for evaluation and potential

assay changes per team discussions on pros/cons of technology

-Meeting with field/service and sales representatives

-Generate reports and presentations for project groups

-Cell based assay for chemistry support-LiCor Technology

-Troubleshoot liquid handling and microplate readers/stackers (BioTek) and fix/repair as necessary.

-Assay development for support of 384-well HTS screening and follow up assays to support lead

generation chemistry efforts for various projects. This includes both cell and enzyme based assay

development and characterization.

-Developed first high throughput 384-well ELISA at Array, allowing secondary screening (or assays) to

be performed on Biomek FX robotic platforms.

-Utilized FRET based technologies for running screens and secondary assays (LanthScreen, LanceUltra,

etc).

-Automate assays to robotic platforms for increased throughput.

-Support assays for project teams moving forward on drug candidates.

Nov 2006-August 2007

Research Associate II

SomaLogic, Inc.

Assay development

-Magnetic Separation assay development for large scale oligo-based assays.

-Assist group in developing assays for use in clinical settings for protein diagnostics using Aptamer

technology.

-Extensive use and development of QPCR, Luminex, and Microarray platforms

July 2006-Nov 2006

Research Associate III

CV Therapeutics, Inc Drug discovery for cardiovascular diseases

Discovery Research

-Promotion; List of tasks below.

Oct. 2004-July 2006

Research Associate II

CV Therapeutics, Inc.

Discovery Research

-Area of atherosclerosis, inflammation, cholesterol transport, metabolic syndrome, and diabetes.

-Lipid extraction, lipoprotein assays and HPLC for fatty acid profiles.

-Gas Chromatography, Fatty Acid Methyl Ester (FAME) method for lipid profiling.

-Assay development for screening drugs for potential candidates using HPLC.

-Real-time PCR for gene expression analysis

-Responsible for streamlining our qPCR and reverse transcription protocols. I validated several

commercial kits for both our qPCR and RT reactions and managed to gain 4 fold sensitivity over our

current protocols and significant cost savings and ease of use for the company/group. Results are pending

publication in vendor printed technical product magazine.-Responsible for in-vitro portion on a new drug

discovery team using cell based and microsomal based assays. This included full maintenance of cell

lines, compound libraries from a CRO and in house chemistry, data analysis and presentation of data to

senior and executive members.

-Designed and initiated metabolism studies in primary rat hepatocytes for compound stability assays.

-CaCo-2 membrane permeability assays.

-Established and optimized siRNA protocols for the group yielding first time results of >95% gene

knockdown in THP-1 cell line with the ability to differentiate and maintain selective gene knockdown for

>5 days

-Substrate/enzyme biochemical assays are being used to elucidate candidates.

-Responsibilities are large in maintaining forward progress and input on a new project.

-Assay development and proof of concept studies are being experimented with, and project input for

ideas/modifications to processes are requested of me.

-ELISA based assays for biomarkers.

-Other techniques include high throughput Transcription Factor blots, Westerns, primary (PBMCs) and

immortalized cell lines for in-vitro cell based assays to elucidate mechanisms surrounding lipid loaded

macrophages and the inflammatory events in atherosclerotic lesions.

-

Oct. 2003-Oct. 2004

Lab Manager/ Research Associate II

Stanford University Medical Center, Palo Alto, CA

Department of General Surgery

Promotion; for list of tasks see below.

Oct. 2002-Oct. 2003

Lab Manager/ Research Associate I

Stanford University Medical Center, Palo Alto, CA

Department of General Surgery

Established Stanford University’s first Trauma/Shock molecular biology laboratory.

-Responsible for networking with multiple sales professionals to outfit the lab with the most advanced

technologies while maintaining a stringent budget.

This included exhaustive research for purchasing a new Real-Time PCR machine, adapting the labs’

past protocols to make best use of newer technologies and intense interaction with the technical vendor

representatives, as we were one of the first labs to have the new machine.

-Designed and outfitted lab

with full tissue culture facility

Current research has begun using THP-1 human monocytes that are chemically differentiated into

mature macrophages. We are investigating how IL-6 and insulin, given in various combinations, effects

macrophages in-vitro using an LPS pro-inflammatory stimulatory mechanism (TLR4 signaling).

-Real-Time PCR analysis of pro-inflammatory cytokines, as well as a newer family of suppressors of

cytokine signaling (SOCS) genes are examined to ultimately investigate the “Friend or Foe” conundrum

of IL-6 in the clinical trauma patient.

-Supervised, instructed, and directed two undergraduate student projects for the 2003 summer term:

Performed RNA isolation from two separate swine hemorrhagic shock models.

Utilized Real-Time PCR (Taqman chemistry) for the expressional fold analysis of pro-inflammatory

cytokine genes.

Performed Western Blots on multiple proteins for post translational activities.

-Able to swiftly learn new protocols for laboratory management technique, California regulations,

institutional financial responsibility, and many other government/institutional policies required for

laboratory management.

-Pursue new opportunities to advancing the current research methodologies.

-Collaborate in professional interaction with surgeons, residents, and other medical professionals.

-Continue previous research interest from our former lab at Baylor College of Medicine as well as

implement new collaborations and avenues for advancement of our current studies.

-Seated on Stanford University’s Emergency Task Force committee

May 2002-Oct. 2002

Research Technician II

Baylor College of Medicine, Houston, TX.

Departments of General Surgery and Infectious Disease

Developed a large animal model of hemorrhagic shock for the molecular dissection of critical pathways

leading up to multiple organ dysfunction syndrome (MODS).

-Primary focus was on signaling pathways involving NFκB (JAK/STAT) and its downstream cascade of

cytokines during hemorrhagic shock.

-Assisted during surgery as swine underwent a Grade V liver injury (initiation of hemorrhagic shock) and

subsequent administration of placebo or test compound (IL-6).

-Performed quantitative RT-PCR to determine expression levels of various cytokines.

-ELISA kits for similar interests were utilized.

-EMSA assays were used for detection of Stat 3 and NFκB complexes.

May 2001-May 2002

Research Technician I

Baylor College of Medicine, Houston, TX.

Department of Allergy, Immunology, and Rheumatology

Project research involving molecular mechanics of the effects of female hormones on hemorrhagic shock

following trauma.

-Engineered chemically competent cells to be utilized for bacterial expression of various cloned genes.

-Performed transformations and subsequent transfections of HeLa cells with various receptors for signal

transduction interest. The estrogen (E2) receptor being of particular interest.

-Utilized the luciferase gene as a reporter assay for detection of transcript(s).

-Main pathways of concern were Jak/Stat along with NFκB regulation.

-Responsible for optimizing protein extraction protocols for Electromobilty Shift Assays (EMSA) for

detecting post transcriptional activity.

-Assisted graduate students in Southern analysis, RPA protection assays, and Knock-out mouse

constructs.

-Performed Western Blot assays.

-Other responsibilities included maintaining the functional aspects of the lab (ordering, budget, equipment

training, etc.).

Sept. 2000-April 2001

Assistant for Practicing Physician

Allergy and Internal Medicine Specialists, Durango, CO.

Responsibilities included patient contact and proper professional conduct of the patient-doctor

relationship. Assessment of vitals and medical history were required, as well as flexibility to assist in all

areas of the practice.

May-August 1997

May-August 1998

May-August 1999

Deck Hand/ 1st Mate

Heritage Boats, Inc., M/V Leylon Sneed, St. Thomas, USVI.

Deck hand (1997) and first mate (1998-99) on a 115-foot United States Coast Guard inspected Vessel.

Responsibilities included being second in command under the captain holding responsibilities for the

safety of the crew, vessel, and 149 guests, speaking in front of large groups of people, troubleshooting,

repair and maintenance.

Volunteer Positions

May-August 2000 Cytogenetics Department at Penrose Hospital, Colorado Springs, CO.

Initiated a large pathology database. Studied chromosomal abnormalities.

Professional interaction with pathologists as well as hospital employees was expected.

Oct.1998- May 2000 Centura Community Health Clinic, Durango, CO.

Assisted in patient care, filing medical charts, and bookkeeping.

Personal Attributes

Held various supervisory positions, mentored medical and undergraduate students, great interpersonal

skills, exceptional computer skills (MS Office, Photoshop, Prism, minor networking, etc.), technically

savvy, strong communication skills, detail oriented, dedicated to excellence, able to work efficiently

under stressful situations, good problem solver, excellent time management skills, excellent

troubleshooting skills, efficiently draw conclusions from data, team spirit, good humored, work well

independently or as a team, highly motivated, ambitious, persistent, and dependable.

Lab Skills

Luminex, ELISA, cell-based assays, siRNA, SDS-PAGE, Western blot, Electromobility Shift Assay

(EMSA), Real-Time PCR (TaqMan, SYBR chemistries), RT-PCR, HPLC, Gas Chromatography-Fatty

Acid Methyl Ester (FAME), FPLC, Beckman FX Robotics, 384-well pipetting and liquid handling

stations, various microplate readers including Perkin Elmer Envisions, Molecular Devices Spectramax

(96 and 3840-well),, TLC, Gel electrophoresis, RNA/DNA/Protein purification, mammalian tissue

culture,, transformation, recombinant DNA techniques, transfection, gel purification, radioactive work,

protocol optimization, assay development, and various microbiological techniques.

Firm signal transduction knowledge.

CourseWork:

Professional Development Short Courses:

Methods in Drug Discovery: Flourescence Assays. Palm Springs, CA., Jan 21-22, 2008.

Enzyme Binding Assays in Drug Discovery. Palm Springs, CA., Jan 22-23, 2008.

Publications:

Koltun, D.O., Parkhill, E.Q., Vasilvich, N.I., Glushkov, A.I., Zilbershtein, T.M., Ivanov, A.V., Cole,

A.G., Henderson, I., Zautke, N.A., Brunn, S.A., Mollova, N., Leung, K., Chisholm, J.W., Zablocki, J.

Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors. Bioorganic

& Medicinal Chemistry Letters (2009). Accepted February 3, 2009.

Brundage, Susan I. MD, MPH; Kirilcuk, Natalie N. MD, MS; Lam Jason C. BS; Spain, David A. MD;

Zautke, Nathan A. BS. Insulin Increases the Release of Pro-inflammatory Mediators. Journal of

Trauma-Injury Infection & Critical Care. 65(2):367-372, August 2008.

SI Brundage, NA Zautke, DA Spain, LC Lam, MA Mastrangelo, JM Macaitis, DJ Tweardy.

Interleukin-6 Infusion Blunts Pro-inflammatory Cytokine Production Without Causing Systemic

Toxicity in a Swine Model of Uncontrolled Hemorrhagic Shock. J. of Trauma. 2004 Nov;57(5):970-7;

discussion 977-8.

Watters JM, Brundage SI, Todd SR, Zautke NA, Stefater JA, Lam JC, Muller PJ, Malinoski D, and

Schreiber MA. Resuscitation with Lactated Ringer’s Does Not Increase Inflammatory Response in a

Swine Model of Uncontrolled Hemorrhagic Shock. Shock. 2004. Sept;22(3):283-7.

Brundage, S., Schreiber, M., Holcomb J., Zautke, N., Mastrangelo, MA., Xq, X.,Macaitis, J., and

Tweardy, D. 2003. Amplification of the Pro-Inflammatory Transcription Factor Cascade Increases with

Severity of Uncontrolled Hemorrhage in Swine. J. of Surg. Res. 2003. Jul;113(1):74-80.

Abstracts:

Steven W. Andrews, Karyn S. Bouhana, Renata Impastato, Yutong Jiang, Ross Wallace, Dylan P.

Hartley, Mary Geck Do, Ira von Carlowitz, Robyn Hamor and Nathan A. Zautke. Array BioPharma,

Inc. Boulder, CO. Effects of a Potent, Selective Kinase Inhibitor of Neurotrophin Receptors TrkA, TrkB

and TrkC in a Model of Inflammatory Pain. Keystone Symposium ‘Neurobiology of Pain and

Analgesia’. Santa Fe, NM.

Dmitry O. Koltun, Eric Q. Parkhill, Natalya I. Vasilevich, Andrei I. Glushkov, Timur M. Zilbershtein,

Aleksei V. Ivanov, Andrew G. Cole, Ian Henderson, Nathan A. Zautke, Sandra A. Brunn, Nevena

Mollova, Dwan Leung, Richard M. Lawn, Jeffery W. Chisholm, Jeff Zablocki. CV Therapeutics Inc.,

Palo Alto CA, USA and Asinex Ltd, Moscow, Russia. Potent, Selective, and Metabolically Stabel

Stearoyl-CoA-Desaturase (SCD) Inhibitors for the Treatment of Obesity and Diabetes. 236th ACS

National Meeting and Symposia. Philidelphia, PA. USA. August 17-21, 2008.

Thomas Mikita, Angie Marson, Nathan Zautke, and Richard M. Lawn. Altered TLR4 Signaling

Response Observed in OxLDL pre-treated Human Macrophages. Gordon Research Conference for

Vascular Cell Biology, Ventura, CA, February 6-11, 2005.

Brundage SI, Spain DA, Lam JC, and Zautke NA. Interleukin-6 After LPS Decreases Macrophage

Tumer Necrosis Factor Alpha Production. Association for Academic Surgeons, Houston, TX, November

11-13, 2004.

Brundage SI, Zautke NA, Lam JC, Dicker RA, and Spain DA. Insulin Increases the Release of Pro-

inflammatory Mediators. The American Associate for the Surgery of Trauma, Maui, HI, September 20-

October 2, 2004.

Zautke NA, Lam JC, Holcomb JB, Spain DA, Tweardy DJ, and Brundage SI. TNF-alpha Levels do not

Increase in Ileum in a Swine Model of Uncontrolled Hemorrhage. Shock Society, Halifax, Nova Scotia,

June 5-8, 2004.

Zautke NA, Lam JC, Holcomb JB, Spain DA, Tweardy DJ, and Brundage SI. TNF-alpha mRNA

Expression Decreases in Swine Ileum During Shock. Proceedings of the 6th World Congress on Trauma,

Shock, and Sepsis, Munich, Germany, March 2-6, 2004.

Brundage SI, Watters J, Zautke NA, Stefater JA, Todd R, Lam JC, and Schreiber MA. Lactated

Ringer’s Does Not Increase Inflammation After Shock. Proceedings of the 6th World Congress on

Trauma, Shock, and Sepsis, Munich, Germany, March 2-6, 2004.

Watters JM, Todd SR, Brundage SI, Zautke NA, Stefater JA, Lam JC, Malinoski D, and Schreiber MA.

Resuscitation with Lactated Ringer’s does Not Increase the Inflammatory Response in a Swine Model of

Uncontrolled Hemorrhagic Shock. Society of University Surgeons, St. Louis, MO, February 11-14,

2004.

Brundage SI, Schreiber MA, Holcomb JB, Zautke NA, Mastrangelo MA, Xu XQ, Macaitis JM, and

Tweardy DJ. Recombinant Activated Factor VII for Adjunctive Hemorrhage Control Reduces Nuclear

Factor Kappa Beta Activation in a Hypothermic Swine Model of Uncontrolled Hemorrhagic Shock.

Shock Society, Phoenix, AZ, June 8, 2003.

Lee, S., Nichino, N., Zautke, N., Teixeira, T., Stewart, D., Mastrangelo, M., Yu, B., Brundage, S.,

Tweardy, D., Yu-Lee, L. Anti-inflammatory Effects of Estrogen and Prolactin During Hemorrhagic

Shock. The Endocrine Society, San Francisco, CA, June 19-22, 2002.

Contact this candidate